Clinical Trials Logo
  1. Home
  2. Digestive System Neoplasms
  3. NCT02781532
  4. Details
NCT02781532 Clinical Trial

Evaluation of Predictive Visual Analog Scale (VAS) for Determining the Ingesta of Patients Carrying a Digestive Cancer

Digestive System Neoplasms Clinical Trial

Clinical Trial Details — Status: Completed

Administrative data
NCT number NCT02781532
Other study ID # 14-PP-05
Secondary ID
Status Completed
Phase N/A
First received May 20, 2016
Last updated May 23, 2016
Start date April 2014
Est. completion date January 2015

Study information
Verified date May 2016
Source Centre Hospitalier Universitaire de Nice
Contact n/a
Is FDA regulated No
Health authority France: Commission nationale de l'informatique et des libertés
Study type Observational

Clinical Trial Summary

The main objective of our study is to determine if the evaluation of ingesta of cancer patients by VAS (on the day of hospitalization) is able to predict the actual ingesta of patients during hospitalization (for patients malnourished, at risk of malnutrition or risk free).

Recruitment information / eligibility
Status Completed
Enrollment 100
Est. completion date January 2015
Est. primary completion date January 2015
Accepts healthy volunteers No
Gender Both
Age group 18 Years and older
Eligibility Inclusion Criteria:

- Patients aged over 18 years

- Admitted to hospital for systemic therapy of gastrointestinal cancer

- Signature of the non-opposition.

Exclusion Criteria:

- Patients who because of their affection will fasted more than 12:00 during the three days preceding hospitalization.

- Artificial nutrition Patients

Study Design

Observational Model: Cohort, Time Perspective: Prospective

Related Conditions & MeSH terms

Locations
Country Name City State
France CHU de Nice France

Sponsors (1)
Lead Sponsor Collaborator
Centre Hospitalier Universitaire de Nice

Country where clinical trial is conducted

France, 

Outcome
Type Measure Description Time frame Safety issue
Primary Evaluation of ingesta Evaluation of ingesta will be done using SAV scale. 3 days No
See also
  Status Clinical Trial Phase
Recruiting NCT06026800 - Clinical Study of Personalized mRNA Vaccine Encoding Neoantigen in Combination With Standard First-line Treatment in Subjects With Advanced Digestive System Neoplasms Phase 1
Recruiting NCT06019702 - Clinical Study of Personalized mRNA Vaccine Encoding Neoantigen Alone in Subjects With Advanced Digestive System Neoplasms Phase 1
Recruiting NCT06026774 - Clinical Study of Personalized mRNA Vaccine Encoding Neoantigen in Subjects With Resected Digestive System Neoplasms Phase 1
Completed NCT02909452 - Continuation Study of Entinostat in Combination With Pembrolizumab in Patients With Advanced Solid Tumors Phase 1
Active, not recruiting NCT05602935 - Efficacy and Safety of SOX Regimen Combined With Camrelizumab as Neoadjuvant Treatment in Locally Advanced Gastric Cancer: a Phase II, Single-arm Study Phase 2
Recruiting NCT04518852 - TACE, Sorafenib and PD-1 Monoclonal Antibody in the Treatment of HCC Phase 2
Completed NCT03717298 - Evaluation of Ocoxin-Viusid® in Advanced Pancreatic Adenocarcinoma Phase 2
Recruiting NCT05322486 - Palliative Primary Tumor Resection in Minimally Symptomatic Patients With Colorectal Cancer and Synchronous Unresectable Metastases
Recruiting NCT04556344 - Effectiveness of an Educational Intervention Aimed at Increasing the Emotional Competencies of Patients Under Surveillance After Antineoplastic Treatment of Oesogastric or Bronchopulmonary Cancer N/A
Terminated NCT03306693 - Educational Intervention to Increase the Emotional Competence of Patients With Oesogastric and Bronchopulmonary Cancers N/A
Active, not recruiting NCT01037049 - Optimum Timing for Surgery After Pre-operative Radiotherapy 6 vs 12 Weeks Phase 2
Recruiting NCT02208804 - Surefire Infusion System vs. Standard Microcatheter Use During Holmium-166 Radioembolization Phase 2/Phase 3
Completed NCT04080843 - Anlotinib Hydrochloride Capsules Combined With CAPEOX in RAS and BRAF Wild-type mCRC Patients Phase 2
Recruiting NCT03303495 - A Study of 2nd-line FOLFIRI ± Bevacizumab vs. Irinotecan ± Bevacizumab in mCRC Phase 3
Terminated NCT04644315 - A Home-Based Approach Study to Evaluate the Efficacy and Safety of Alectinib in Locally-Advanced or Metastatic ALK-Positive Solid Tumors Phase 2
Recruiting NCT03271255 - Apatinib Versus Bevacizumab in Second-line Therapy for Colorectal Cancer(ABST-C) Phase 2
Recruiting NCT03221335 - EUS-guided RFA for Solid Abdominal Neoplasms N/A
Recruiting NCT02487017 - DC-CIK Combined With TACE in the Treatment of Hepatocellular Carcinoma Phase 2
Not yet recruiting NCT01556815 - Sorafenib Combined With Transarterial Chemoembolization in Treating HBV-infected Patients With Intermediate Hepatocellular Carcinoma Phase 2
Recruiting NCT04949282 - Spanish Series of Patients Treated With the Radionuclide Lutetium177